Search in:

Expert Opinion on Investigational Drugs Volume 25, 2016 - Issue 2

Submit an article Journal homepage

2,467

Views

CrossRef citations to date

Altmetric

Reviews

An overview of new GLP-1 receptor agonists for type 2 diabetes

Brian TomlinsonResearch Center for Translational Medicine, Shanghai East Hospital Affiliated to Tongji University School of Medicine, Shanghai, China;Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

Miao HuDepartment of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

Yuzhen ZhangResearch Center for Translational Medicine, Shanghai East Hospital Affiliated to Tongji University School of Medicine, Shanghai, China

Paul ChanDivision of Cardiology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei city, TaiwanCorrespondence[email protected]

Zhong-Min LiuDepartment of Cardiac Surgery, Shanghai East Hospital, Tongji University, Shanghai, ChinaCorrespondence[email protected]

Pages 145-158 | Received 22 Oct 2015, Accepted 18 Nov 2015, Published online: 17 Dec 2015

Cite this article
https://doi.org/10.1517/13543784.2016.1123249
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Papers of special note have been highlighted as:
Google Scholar
• either of interest
Google Scholar
•• of considerable interest
Google Scholar
Stumvoll M, Goldstein BJ, Van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–1346.
PubMed Web of Science ®Google Scholar
International Diabetes Federation. IDF diabetes atlas. 6th. Brussels, Belgium: International Diabetes Federation;2014. Update. Available at: http://www.idf.org/diabetesatlas. (Accessed on 14 Aug 2015).
Google Scholar
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–846.
PubMed Web of Science ®Google Scholar
Cho YM, Merchant CE, Kieffer TJ. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther. 2012;135:247–278.
PubMed Web of Science ®Google Scholar

• Comprehensive review of GLP-1 receptor agonists (GLP-1RAs).

Tahrani AA, Piya MK, Kennedy A, et al. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther. 2010;125:328–361.
PubMed Web of Science ®Google Scholar
Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378:182–197.
PubMed Web of Science ®Google Scholar

• A useful review on the management of type 2 diabetes.

Burcelin R, Knauf C, Cani PD. Pancreatic alpha-cell dysfunction in diabetes. Diabetes Metab. 2008;34(Suppl 2):S49S55.
Google Scholar
Bailey CJ. Safety of antidiabetes medications: An update. Clin Pharmacol Ther. 2015;98:185–195.
PubMed Web of Science ®Google Scholar
Lund A, Knop FK, Vilsboll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med. 2014;25:407–414.
PubMed Web of Science ®Google Scholar

• A recent review on the properties of the currently available GLP-1RAs.

Del Prato S, Bianchi C, Marchetti P. beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab Res Rev. 2007;23:518–527.
PubMed Web of Science ®Google Scholar
Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386–399.
PubMed Web of Science ®Google Scholar
Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinediones–what do meta-analyses really tell us?. Diabetes Obes Metab. 2010;12:1023–1035.
PubMed Web of Science ®Google Scholar
Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36:2288–2296.
PubMed Web of Science ®Google Scholar

•• Detailed review on the effects of glucose-lowering drugs on cardiovascular outcomes.

Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14:505–524.
PubMed Web of Science ®Google Scholar
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443.
PubMed Web of Science ®Google Scholar
Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279S284.
Google Scholar
Finan B, Clemmensen C, Muller TD. Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol. 2015. DOI:10.1016/j.mce.2015.07.003. [ Epub ahead of print].
PubMed Web of Science ®Google Scholar

•• An important review on the emerging GLP-1-based agonists.

Lund A, Knop FK, Vilsboll T. Emerging GLP-1 receptor agonists. Expert Opin Emerg Drugs. 2011;16:607–618.
PubMed Web of Science ®Google Scholar
Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283.
PubMedGoogle Scholar
Shyangdan DS, Royle P, Clar C, et al. Gl ucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Syst Rev. 2011;(10):CD006423. DOI:10.1002/14651858.CD006423.pub2
Google Scholar
Gallwitz B. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents. Drugs. 2011;71:1675–1688.
PubMed Web of Science ®Google Scholar
Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Bmj. 2012;344:d7771.
PubMed Web of Science ®Google Scholar
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742.
PubMed Web of Science ®Google Scholar

•• A good summary of GLP-1RAs for the management of type 2 diabetes.

Parker HE, Reimann F, Gribble FM. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med. 2010;12:e1.
PubMed Web of Science ®Google Scholar
Holst JJ, Deacon CF. Is there a place for incretin therapies in obesity and prediabetes?. Trends Endocrinol Metab. 2013;24:145–152.
PubMed Web of Science ®Google Scholar
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–1439.
PubMed Web of Science ®Google Scholar
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.
PubMed Web of Science ®Google Scholar
Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929–2940.
PubMed Web of Science ®Google Scholar
Bagger JI, Knop FK, Lund A, et al. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:737–745.
PubMed Web of Science ®Google Scholar
Ross SA, Brown JC, Dupre J. Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes. 1977;26:525–529.
PubMed Web of Science ®Google Scholar
Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470–512.
PubMed Web of Science ®Google Scholar
Nauck MA, Vardarli I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. Diabetologia. 2011;54:10–18.
PubMed Web of Science ®Google Scholar
Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?. Diabetes. 2010;59:1117–1125.
PubMed Web of Science ®Google Scholar
Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301–307.
PubMed Web of Science ®Google Scholar
Mentis N, Vardarli I, Kothe LD, et al. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes. 2011;60:1270–1276.
PubMed Web of Science ®Google Scholar
Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009;124:113–138.
PubMed Web of Science ®Google Scholar
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
PubMed Web of Science ®Google Scholar
Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280–1290.
PubMed Web of Science ®Google Scholar
Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995;358:219–224.
PubMed Web of Science ®Google Scholar
Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–2276.
PubMed Web of Science ®Google Scholar
Buteau J, El-Assaad W, Rhodes CJ, et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia. 2004;47:806–815.
PubMed Web of Science ®Google Scholar
De Marinis YZ, Salehi A, Ward CE, et al. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell Metab. 2010;11:543–553.
PubMed Web of Science ®Google Scholar
Fineman MS, Cirincione BB, Maggs D, et al. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab. 2012;14:675–688.
PubMed Web of Science ®Google Scholar
Hare KJ, Vilsboll T, Asmar M, et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes. 2010;59:1765–1770.
PubMed Web of Science ®Google Scholar
Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:2719–2725.
PubMed Web of Science ®Google Scholar
Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981–E988.
PubMed Web of Science ®Google Scholar
Shirazi R, Palsdottir V, Collander J, et al. Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6. Proc Natl Acad Sci U S A. 2013;110:16199–16204.
PubMed Web of Science ®Google Scholar
Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Investig. 2014;124:4223–4226.
PubMed Web of Science ®Google Scholar
Meier JJ, Gethmann A, Gotze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006;49:452–458.
PubMed Web of Science ®Google Scholar
Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110:43–52.
PubMed Web of Science ®Google Scholar
Smilowitz NR, Donnino R, Schwartzbard A. Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease. Circulation. 2014; 129:2305–2312.
PubMed Web of Science ®Google Scholar
Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788–1803.
PubMed Web of Science ®Google Scholar
Tate M, Chong A, Robinson E, et al. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol. 2015;172:721–736.
PubMed Web of Science ®Google Scholar

• Recent review of the potential mechanisms of drugs acting through GLP-1 on cardiovascular disease.

Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187–215.
PubMed Web of Science ®Google Scholar
Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011;9:258–270.
PubMed Web of Science ®Google Scholar
Pirillo A, Norata GD, Catapano AL. Postprandial lipemia as a cardiometabolic risk factor. Curr Med Res Opin. 2014;30:1489–1503.
PubMed Web of Science ®Google Scholar
Stefanutti C, Labbadia G, Athyros VG. Hypertriglyceridaemia, postprandial lipaemia and non-HDL cholesterol. Curr Pharm Des. 2014;20:6238–6248.
PubMed Web of Science ®Google Scholar
Trahair LG, Horowitz M, Stevens JE, et al. Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes. Diabetologia. 2015;58:1769–1778.
PubMed Web of Science ®Google Scholar

• Review of many of the effects of GLP-1RAs.

Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110:26–37.
PubMed Web of Science ®Google Scholar
Consoli A, Formoso G. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opin Drug Saf. 2015;14:207–218.
PubMed Web of Science ®Google Scholar
Yabe D, Kuwata H, Usui R, et al. Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points. Curr Med Res Opin. 2015;31:1267–1270.
PubMed Web of Science ®Google Scholar
Jendle J, Martin SA, Milicevic Z. Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. Expert Opin Investig Drugs. 2012;21:1463–1474.
PubMed Web of Science ®Google Scholar
Malone J, Trautmann M, Wilhelm K, et al. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2009;18:359–367.
PubMed Web of Science ®Google Scholar
Scott LJ. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus. Drugs. 2014;74:2161–2174.
PubMed Web of Science ®Google Scholar
Drab SR. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus. Pharmacotherapy. 2009;29:43S54S.
Google Scholar
Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373:11–22.
PubMed Web of Science ®Google Scholar

• The first study to show the weight-reducing effects of a GLP-1RA in obese nondiabetics.

Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. Jama. 2015;314:687–699.
PubMed Web of Science ®Google Scholar
Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166:823830 e5.
Web of Science ®Google Scholar
Christensen M, Knop FK, Vilsboll T, et al. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs. 2011;20:549–557.
PubMed Web of Science ®Google Scholar
Bronden A, Naver SV, Knop FK, et al. Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opin Drug Metab Toxicol. 2015;11:1493–1503.
PubMed Web of Science ®Google Scholar
Fisher M, Petrie MC, Ambery PD, et al. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015;3:697–703.
PubMed Web of Science ®Google Scholar
Sanford M. Dulaglutide: first global approval. Drugs. 2014;74:2097–2103.
PubMed Web of Science ®Google Scholar
Rosenstock J, Balas B, Charbonnel B, et al. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care. 2013;36:498–504.
PubMed Web of Science ®Google Scholar
Gier B, Butler PC, Lai CK, et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97:121–131.
PubMed Web of Science ®Google Scholar
Monami M, Dicembrini I, Nardini C, et al. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res Clin Pract. 2014;103:269–275.
PubMed Web of Science ®Google Scholar
Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs–FDA and EMA assessment. N Engl J Med. 2014;370:794–797.
PubMed Web of Science ®Google Scholar

• Review of the pancreatic safety issues with incretin-based drugs.

Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011;96:1695–1702.
PubMed Web of Science ®Google Scholar
Sivertsen J, Rosenmeier J, Holst JJ, et al. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012;9:209–222.
PubMed Web of Science ®Google Scholar
Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3:pii:e001986.
Web of Science ®Google Scholar
Kalra S, Gupta Y. Injectable Coformulations in Diabetology. Diabetes Ther. 2015;6:101–111.
PubMed Web of Science ®Google Scholar
Rendell M. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes. Drugs Today (Barc). 2015;51:185–196.
PubMed Web of Science ®Google Scholar
Lau J, Bloch P, Schaffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58:7370–7380.
PubMed Web of Science ®Google Scholar
Nauck MA, Petrie JR, Sesti G, et al. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes Care. 2015;pii:dc150165. [Epub ahead of print].
Web of Science ®Google Scholar
Novo Nordisk successfully completes first phase 3a trial with semaglutide in people with type 2 diabetes. [ cited 2015 19 Oct]. Available from: http://globenewswire.com/news-release/2015/07/10/751271/0/en/Novo-Nordisk-successfully-completes-first-phase-3a-trial-with-semaglutide-in-people-with-type-2-diabetes.html.
Google Scholar
Steinert RE, Poller B, Castelli MC, et al. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther. 2009;86:644–650.
PubMed Web of Science ®Google Scholar
Henry RR, Logan D, Alessi T, et al. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes. Clin Ther. 2013;35:63445,e1.
Web of Science ®Google Scholar
Henry RR, Rosenstock J, Logan D, et al. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications. 2014;28:393–398.
PubMed Web of Science ®Google Scholar
Henry RR, Rosenstock J, Logan DK, et al. Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes. Diabetes Care. 2013;36:2559–2565.
PubMed Web of Science ®Google Scholar
Baggio LL, Huang Q, Cao X, et al. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology. 2008;134:1137–1147.
PubMed Web of Science ®Google Scholar
CJC-1134-PC. [ cited 2015 19 Oct]. Available from: http://www.conjuchem.com/pipeline/cjc-1134-pc.
Google Scholar
Hanmi Pharmaceutical. [ cited 2015 Oct 19]. Available from: http://www.hanmipharm.com/ehanmi/handler/Rnd-ProjectBio.
Google Scholar
Superagonistic Mechanism of Increased Glucodynamic and Weight Loss Effects of LAPSCA-Exendin-4 (HM11260C) [Abstract]. Presented at the American Diabetes Association (ADA) 75th Scientific Sessions; 2015 Jun 59; Boston, USA. [cited 2015 Oct 16]. Available from: http://app.core-apps.com/tristar_ada15/abstract/160858d53930b598d64b10f393bc599d.
Google Scholar
A Monthly Dosed GLP-1 Analog for Treatment of Type 2 Diabetes Mellitus [Abstract]. Presented at the American Diabetes Association (ADA) 70th Scientific Sessions; 2010 Jun 25 - 29; Orlando(FL). [cited 2015 Oct 19]. Available from: http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=79329.
Google Scholar
Significant Effects of HM11260C on Body Weight over 20 Weeks in Obese Subjects without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study [Abstract]. Presented at the American Diabetes Association (ADA) 75th Scientific Sessions; 2015 Jun 5–9; Boston, USA. [cited 2015 Oct 16]. Available from: http://app.core-apps.com/tristar_ada15/abstract/1678f29f2a56ce35baedcc25f3959e9d.
Google Scholar
Weekly Subcutaneous Doses of Glymera (PB1023) a Novel GLP-1 Analogue Reduce Glucose Exposure Dose-Dependently [Abstract]. Presented at the American Diabetes Association (ADA) 72th Scientific Sessions; 2012 Jun 812; Philadelphia (PA). [cited 2015 Oct 16]. Available from: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=761b96ad-5b5d-4d0c-80d2-a7cb9c3b63fa&cKey=657f214c-9b3b-4072-aaa5-d48f4dfca4f7&mKey=0f70410f-8df3-49f5-a63d-3165359f5371.
Google Scholar
XTEN-Modified Glucagon and Exenatide Constructs for Improving Glycemic Control in Type 1 and Type 2 Diabetes [Abstract]. Presented at the American Diabetes Association (ADA) 70th Scientific Sessions; 2010 Jun 25 - 29; Orlando (FL). [cited 2015 Oct 19]. Available from: http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=79329.
Google Scholar
Noninferior Delay in Gastric Emptying vs. Liraglutide and Favorable Glucometabolic Profile following Treatment with LAPSExendin-4 (HM11260C) in Subjects with Type 2 Diabetes Mellitus (T2DM).[Abstract]. Presented at the American Diabetes Association (ADA) 75th Scientific Sessions; 2015; Jun 5–9; Boston, USA. [cited 2015 Oct 16]. Available from: http://app.core-apps.com/tristar_ada15/abstract/160858d53930b598d64b10f39345322d.
Google Scholar
TTP054, a Novel, Orally-Available Glucagon-like Peptide-1 (GLP-1) Agonist, Lowers HbA1c in Subjects with Type 2 Diabetes Mellitus (T2DM). [Abstract]. Presented at the American Diabetes Association (ADA) 74th Scientific Sessions; 2014 Jun 1317; San Francisco (CA). [cited 2015 Oct 19]. Available from: http://app.core-apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc8638a09fb8.
Google Scholar
Koole C, Wootten D, Simms J, et al. Differential impact of amino acid substitutions on critical residues of the human glucagon-like peptide-1 receptor involved in peptide activity and small-molecule allostery. J Pharmacol Exp Ther. 2015;353:52–63.
PubMed Web of Science ®Google Scholar
Paul SK, Klein K, Maggs D, et al. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol. 2015;14:10.
PubMed Web of Science ®Google Scholar
Schellenberger V, Wang CW, Geething NC, et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol. 2009;27:1186–1190.
PubMed Web of Science ®Google Scholar
TTP273, an Orally-Available Glucagon-like Peptide-1 (GLP-1) Agonist, Notably Reduces Glycemia in Subjects with Type 2 Diabetes Mellitus. [Abstract] Presented at the American Diabetes Association (ADA) 74th Scientific Sessions; 2014 Jun 1317; San Francisco (CA). [cited 2015 Oct 19]. Available from: http://app.core-apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc8638a09315.
Google Scholar
NN9924 ClinicalTrials. [ cited 2015 Oct 19]. Available from: https://clinicaltrials.gov/ct2/results?term=NN9924&Search=Search.
Google Scholar
ARI-1732TS, a Long Acting, Protease Resistant, Orally Active GLP-1 Analog. [Abstract] Presented at Diabetes Summit 2015; 2015 Apr 2729; Boston, USA. [cited 2015 Oct 19]. Available from: http://www.giiconference.com/gtc321496/diabetes-drug-discovery-development-agenda.shtml
Google Scholar
Cadila Gets DCGT Approval For ZYOG1 Clinical Trial. [ cited 2015 Oct 16]. Available frpm: http://www.rttnews.com/1338897/cadila-gets-dcgt-approval-for-zyog1-clinical-trial.aspx
Google Scholar
Show study NTC02094521: evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects. [ cited 2015 Oct 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT02094521?term=NN9926&rank=1.
Google Scholar
Show study NTC01978613: Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects. [ cited 2015 Oct19]. Available from: https://clinicaltrials.gov/ct2/show/NCT01978613?term=NN9927&rank=1.
Google Scholar
Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6:19–28.
PubMed Web of Science ®Google Scholar
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
PubMed Web of Science ®Google Scholar
Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13:7–18.
PubMed Web of Science ®Google Scholar
Monami M, Ahren B, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15:112–120.
PubMed Web of Science ®Google Scholar
Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122:16–27.
PubMed Web of Science ®Google Scholar
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
PubMed Web of Science ®Google Scholar

• One of the first cardiovascular outcome studies with a DPP4 inhibitor.

White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
PubMed Web of Science ®Google Scholar

• Another of the first cardiovascular outcome studies with a DPP4 inhibitor.

Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067–2076.
PubMed Web of Science ®Google Scholar
Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373:232–242.
PubMed Web of Science ®Google Scholar

• The cardiovascular outcome study with sitagliptin.

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit.[ cited 2015 Oct 19]. http://www.diabetes.org/newsroom/press-releases/2015/elixa.html.
Google Scholar
Hirshberg B, Katz A. Insights From Cardiovascular Outcome Trials with Novel Antidiabetes Agents: what Have We Learned? An Industry Perspective. Curr Diab Rep. 2015;15:87.
PubMed Web of Science ®Google Scholar
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117–2128.
PubMed Web of Science ®Google Scholar

•• The first outcome study with a sodium-glucose co-transporter 2 inhibitor.

Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care. 2015;38:1638–1642.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

An overview of new GLP-1 receptor agonists for type 2 diabetes

Bibliography

• Comprehensive review of GLP-1 receptor agonists (GLP-1RAs).

• A useful review on the management of type 2 diabetes.

• A recent review on the properties of the currently available GLP-1RAs.

•• Detailed review on the effects of glucose-lowering drugs on cardiovascular outcomes.

•• An important review on the emerging GLP-1-based agonists.

•• A good summary of GLP-1RAs for the management of type 2 diabetes.

• Recent review of the potential mechanisms of drugs acting through GLP-1 on cardiovascular disease.

• Review of many of the effects of GLP-1RAs.

• The first study to show the weight-reducing effects of a GLP-1RA in obese nondiabetics.

• Review of the pancreatic safety issues with incretin-based drugs.

• One of the first cardiovascular outcome studies with a DPP4 inhibitor.

• Another of the first cardiovascular outcome studies with a DPP4 inhibitor.

• The cardiovascular outcome study with sitagliptin.

•• The first outcome study with a sodium-glucose co-transporter 2 inhibitor.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

An overview of new GLP-1 receptor agonists for type 2 diabetes

Bibliography

• Comprehensive review of GLP-1 receptor agonists (GLP-1RAs).

• A useful review on the management of type 2 diabetes.

• A recent review on the properties of the currently available GLP-1RAs.

•• Detailed review on the effects of glucose-lowering drugs on cardiovascular outcomes.

•• An important review on the emerging GLP-1-based agonists.

•• A good summary of GLP-1RAs for the management of type 2 diabetes.

• Recent review of the potential mechanisms of drugs acting through GLP-1 on cardiovascular disease.

• Review of many of the effects of GLP-1RAs.

• The first study to show the weight-reducing effects of a GLP-1RA in obese nondiabetics.

• Review of the pancreatic safety issues with incretin-based drugs.

• One of the first cardiovascular outcome studies with a DPP4 inhibitor.

• Another of the first cardiovascular outcome studies with a DPP4 inhibitor.

• The cardiovascular outcome study with sitagliptin.

•• The first outcome study with a sodium-glucose co-transporter 2 inhibitor.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date